Laurent Bertoletti Highlights Evolving Role of Anticoagulation in Pulmonary Hypertension Treatment
Laurent Bertoletti, University Professor and Hospital Practitioner at Jean Monnet University, Saint-Etienne, shared on LinkedIn:
”Thank you to the scientific council of the French Days of Pulmonary Hypertension RespiFil for the invitation to present an update on the treatment anticoagulant in pulmonary hypertension.
It is an honour to be able to share data from the French registry and to discuss a topic that is as debated as it is crucial for patient care.
The prescription of anticoagulants now seems to be restricted to patients with a validated indication such as a history of MTEV or atrial fibrillation.
The next collective objective is to determine the best therapeutic antithrombotic strategy, in patients with PH-TEC or PH and a validated indication.”
Stay updated with Hemostasis Today.
-
Jan 25, 2026, 15:42Francesco Lo Monaco on Heart Disease Starting Quiet While Your Labs Speak First
-
Jan 25, 2026, 15:33Wilfried Dinh: Why Heart Patients Still Have Events Despite ”Optimal” Cardiovascular Therapy
-
Jan 25, 2026, 15:25Muhammad Ibrahim on Efficacy and Safety of Extended DOACs Use in VTE
-
Jan 25, 2026, 15:08Tushar Pandey on Managing Thrombotic Thrombocytopenic Purpura
-
Jan 25, 2026, 14:55Carolina Contreras Cuevas Shares a Nationwide Study on VTE in PAD
-
Jan 25, 2026, 14:40Jeannie Devereaux Links PRP and Physical Therapy
-
Jan 25, 2026, 14:25Heghine Khachatryan on Anticoagulation After AFib Ablation: New Evidence from NEJM
-
Jan 25, 2026, 12:42Lale Tokgözoğlu on Cardiovascular Risk Factors in Women
-
Jan 25, 2026, 12:32Dino Mehic on Bleeding Assessment Tools and QoL in BDUC